Klodronát … aneb stará láska nerezaví
Využití u karcinomu prsu a karcinomu prostaty

Česká verzia

Authors: J. Abrahámová
Authors place of work: Na Bulovce ve spolupráci se Všeobecnou fakultní nemocnicí a Fakultní Thomayerovou nemocnicí s poliklinikou ; Vedoucí: prof. MUDr. Jitka Abrahámová, CSc. ; Komplexní onkologické centrum Fakultní nemocnice
Published in the journal: Prakt. Lék. 2011; 91(5): 278-283
Category: Of different specialties

Summary

The author resumes knowledge related to usage of bisphosphonates especially clodronate in the treatment of bone metastasis in malignant diseases. Clodronate is the first and currently longest used bisphosphonate in this indication. From realized trials with breast and prostate carcinoma results that in spite of following newest generation of bisphosphonates, clodronate has it´s place in the treatment of bone metastasis. Incidence of breast cancer and prostate cancer are growing, which is documented in the National Oncology Register (NOR).

Key words:
bisphosphonates, clodronate, breast cancer, prostate cancer

Zdroje

1. Tubiana-Hulin, M., Beuzeboc, P., Mauriac, L. et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull. Cancer 2001, 88(7), p. 701-707.

2. Diel, I.J., Jaschke, A., Solomayer, E.F. et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann. Oncol. 2008, 19(12), p. 2007–2011.

3. Aapro, M., Abrahamsson, P.A., Body, J.J. et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008, 19(3), p. 420–432.

4. Heidenreich, A., Hofmann, R., Engelmann, U.H. et al. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J. Urol. 2001, 165(1), p. 136-140.

5. Dearnaley, D.P., Mason, M.D., Parmar, M.K. et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009, 10(9), p. 872-876.

6. Abrahámová, J. Zlepšení kvality života pacientů s kostními metastázami léčených klodronátem. Prakt. Lék. 2007, 87(8), s. 648-654.

7. Data on file. BSP 2010.

8. Demers, L.M., Costa, L., Lipton, A. Biochemical markers and skeletal metastases. Cancer 2000, 88(12 Suppl), p. 2919-2926.

9. Coleman, R.E., Major, P., Lipton, A. et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 2005, 23(22), p. 4925-4935.

10. Kohno, N., Aogi, K., Minami, H. et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol. 2005, 23(15), p. 3314-3321.

11. Saad, F., Gleason, D.M., Murray, R. et al. Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Natl. Cancer Inst. 2004, 96(11), p. 879-882.

12. Berenson, J.R., Lichtenstein, A., Porter, L. et al. Myeloma Aredia Study Group. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Clin. Oncol. 1998, 16(2), p. 593-602.

13. Rosen, L.S., Gordon, D., Tchekmedyian, N.S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004, 100(12), p. 2613-2621.

14. Mulders, P., Miller, K., Tchekmedyian, N.S., Chen, Y.M. Long-term reduction in risk of skeletal complications with zolendronic acid in patients with advanced renal cell carcinoma or bladder cancer. This abstract was presented during the past 22nd Annual EAU Congress, Berlin, 21-24 March 2007.